Showing 1,261 - 1,280 results of 39,340 for search '(( 5 ((non decrease) OR (point decrease)) ) OR ( 100 ((nm decrease) OR (a decrease)) ))', query time: 0.93s Refine Results
  1. 1261
  2. 1262
  3. 1263

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  4. 1264
  5. 1265
  6. 1266
  7. 1267
  8. 1268

    Data Sheet 1_Semaglutide attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis of cardiomyocytes via activation of PKC-S100A9 axis.pdf by Yan Liu (25061)

    Published 2025
    “…In vitro, experiments showed that semaglutide decreased the expression of S100A9 by activating the Protein Kinase C(PKC) pathway, thus inhibiting ferroptosis in cardiomyocytes.…”
  9. 1269

    Data Sheet 2_Semaglutide attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis of cardiomyocytes via activation of PKC-S100A9 axis.docx by Yan Liu (25061)

    Published 2025
    “…In vitro, experiments showed that semaglutide decreased the expression of S100A9 by activating the Protein Kinase C(PKC) pathway, thus inhibiting ferroptosis in cardiomyocytes.…”
  10. 1270

    Table 1_Semaglutide attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis of cardiomyocytes via activation of PKC-S100A9 axis.docx by Yan Liu (25061)

    Published 2025
    “…In vitro, experiments showed that semaglutide decreased the expression of S100A9 by activating the Protein Kinase C(PKC) pathway, thus inhibiting ferroptosis in cardiomyocytes.…”
  11. 1271

    Different response of visASCs to a micro-local oxygen concentration decrease in metabolically active sites of the adipose tissue. by Wilfredo Oliva-Olivera (301968)

    Published 2017
    “…However, hypox-visASCs from MS patients show a lower ability to actively participate in or stimulate the formation of microvascular structures, while they favor the accumulation of CD11C<sup>+</sup> and CD163<sup>+</sup> macrophages in the adipose tissue through their contribution to the increased tissue levels of MCP1. ↑ Increased response; <b>↓</b> Decreased response; → Hypox-visASCs main response NonMS: obese subjects without metabolic syndrome; MS: obese subjects with metabolic syndrome; visASC: visceral adipose tissue-derived multipotent mesenchymal cells; hypox-visASCs: visASC under hypoxia; NOX5: NADPH Oxidase 5; SDF1α: stromal cell-derived factor 1α; VEGF: vascular endothelial growth factor; MCP1: monocyte chemoattractant protein 1; CD11C<sup>+</sup>, CD163<sup>+</sup>: proinflammatory macrophage cell-surface markers.…”
  12. 1272
  13. 1273

    Chitinases (1 μmol in 100 mM sodium acetate buffer, pH 5 by Supansa Pantoom (42379)

    Published 2011
    “…Decreases in free enzyme concentration were determined at different time points from 0–30 min by Bradford's method. …”
  14. 1274
  15. 1275
  16. 1276
  17. 1277
  18. 1278
  19. 1279
  20. 1280